Cerity Partners LLC Grows Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Cerity Partners LLC grew its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 439.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,000 shares of the biopharmaceutical company’s stock after buying an additional 44,800 shares during the period. Cerity Partners LLC’s holdings in Sangamo Therapeutics were worth $36,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SGMO. Commonwealth Equity Services LLC grew its stake in Sangamo Therapeutics by 40.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 95,501 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 27,353 shares in the last quarter. American Century Companies Inc. purchased a new position in Sangamo Therapeutics in the 4th quarter worth approximately $107,000. LPL Financial LLC grew its stake in Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 16,498 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Sangamo Therapeutics in the 4th quarter worth approximately $127,000. Finally, JPMorgan Chase & Co. grew its stake in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 21,793 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.55 on Thursday. The firm has a 50 day moving average price of $0.51 and a 200-day moving average price of $0.76. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.41 and a fifty-two week high of $3.18. The firm has a market cap of $127.08 million, a price-to-earnings ratio of -1.40 and a beta of 1.23.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. The firm had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. As a group, equities research analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 30th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, June 24th. Finally, Barclays lowered their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.